$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000110465914058341 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$293.0K	$475.0K	$0.00
YoY Change	651.28%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.270M	$4.750M	$4.830M
YoY Change	13.58%	-1.66%	-17.01%
% of Gross Profit
Research & Development	$12.05M	$9.978M	$10.73M
YoY Change	19.18%	-6.97%	-21.85%
% of Gross Profit
Depreciation & Amortization	$370.0K	$400.0K	$450.0K
YoY Change	-13.95%	-11.11%	2.27%
% of Gross Profit
Operating Expenses	$17.11M	$14.74M	$16.01M
YoY Change	12.75%	-7.9%	-19.91%
Operating Profit	-$16.82M	-$14.27M	-$16.01M
YoY Change	11.11%	-10.87%	71.23%
Interest Expense	$377.0K	$374.0K	$9.000K
YoY Change	5285.71%	4055.56%	-40.0%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	-$10.00K	$0.00
YoY Change			-100.0%
Pretax Income	-$17.15M	-$14.61M	-$15.35M
YoY Change	17.55%	-4.81%	64.28%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.15M	-$14.61M	-$15.35M
YoY Change	17.55%	-4.79%	64.28%
Net Earnings / Revenue	-5852.9%	-3076.63%
Basic Earnings Per Share
Diluted Earnings Per Share	-$217.4K	-$217.4K	-$309.4K
COMMON SHARES
Basic Shares Outstanding	78.70M shares	64.34M shares	49.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.20M	$78.00M	$74.20M
YoY Change	40.83%	5.12%	-22.55%
Cash & Equivalents	$19.70M	$41.90M	$23.48M
Short-Term Investments	$65.50M	$36.10M	$50.70M
Other Short-Term Assets	$1.762M	$951.0K	$1.978M
YoY Change	3.65%	-51.92%	-26.74%
Inventory
Prepaid Expenses
Receivables	$300.0K	$500.0K	$1.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$87.24M	$79.42M	$77.18M
YoY Change	35.67%	2.91%	-26.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.129M	$3.444M	$4.715M
YoY Change	-28.89%	-26.96%	-14.27%
Goodwill	$11.61M	$11.61M
YoY Change
Intangibles	$23.00M	$23.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$508.0K	$515.0K	$442.0K
YoY Change	27.0%	16.52%	10.5%
Total Long-Term Assets	$38.25M	$38.57M	$5.157M
YoY Change	696.88%	647.95%	-12.59%
TOTAL ASSETS
Total Short-Term Assets	$87.24M	$79.42M	$77.18M
Total Long-Term Assets	$38.25M	$38.57M	$5.157M
Total Assets	$125.5M	$118.0M	$82.34M
YoY Change	81.6%	43.31%	-26.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.30M	$9.900M	$9.000M
YoY Change	37.8%	10.0%	-1.1%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.500M	$1.300M	$400.0K
YoY Change	525.0%	225.0%	-50.0%
Total Short-Term Liabilities	$13.82M	$11.17M	$9.967M
YoY Change	60.78%	12.08%	-44.04%
LONG-TERM LIABILITIES
Long-Term Debt	$11.80M	$13.10M	$100.0K
YoY Change		13000.0%	-80.0%
Other Long-Term Liabilities	$514.0K	$748.0K	$32.70M
YoY Change	-98.49%	-97.71%	62.69%
Total Long-Term Liabilities	$514.0K	$748.0K	$32.80M
YoY Change	-98.49%	-97.72%	59.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.82M	$11.17M	$9.967M
Total Long-Term Liabilities	$514.0K	$748.0K	$32.80M
Total Liabilities	$14.34M	$11.92M	$42.80M
YoY Change	-66.34%	-72.15%	11.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$426.2M	-$409.1M	-$351.7M
YoY Change	16.37%	16.32%
Common Stock	$469.5M	$445.4M	$391.3M
YoY Change	19.54%	13.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.28M	$36.31M	$39.56M
YoY Change
Total Liabilities & Shareholders Equity	$125.5M	$118.0M	$82.34M
YoY Change	81.59%	43.31%	-26.22%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$17.15M	-$14.61M	-$15.35M
YoY Change	17.55%	-4.79%	64.28%
Depreciation, Depletion And Amortization	$370.0K	$400.0K	$450.0K
YoY Change	-13.95%	-11.11%	2.27%
Cash From Operating Activities	-$15.12M	-$11.82M	-$10.26M
YoY Change	11.92%	15.2%	-7.82%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$90.00K	-$210.0K
YoY Change	-14.29%	-57.14%	-75.58%
Acquisitions
YoY Change
Other Investing Activities	-$29.42M	$8.030M	$7.300M
YoY Change	-245.28%	10.0%	-56.39%
Cash From Investing Activities	-$29.47M	$7.930M	$7.100M
YoY Change	-246.04%	11.69%	-55.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.36M	18.26M	-100.0K
YoY Change	-22460.0%	-18360.0%	-75.61%
NET CHANGE
Cash From Operating Activities	-15.12M	-11.82M	-10.26M
Cash From Investing Activities	-29.47M	7.930M	7.100M
Cash From Financing Activities	22.36M	18.26M	-100.0K
Net Change In Cash	-22.23M	14.37M	-3.260M
YoY Change	-438.36%	-540.8%	-175.12%
FREE CASH FLOW
Cash From Operating Activities	-$15.12M	-$11.82M	-$10.26M
Capital Expenditures	-$60.00K	-$90.00K	-$210.0K
Free Cash Flow	-$15.06M	-$11.73M	-$10.05M
YoY Change	12.05%	16.72%	-2.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-11000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409079000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43640000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41904000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43640000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	41904000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38359000	USD
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	36094000	USD
CY2013Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	81999000	USD
CY2014Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	77998000	USD
CY2014Q2	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2014Q2	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	36092000	USD
CY2013Q4	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	82000000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	15600000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	23600000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	14000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18344000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65799059	shares
CY2013Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	15891000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	33731000	USD
CY2013Q4	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	11600000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	11613000	USD
CY2013Q4	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	23000000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q2	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	item
	fold	Number Of Inputs Used To Determine Value Of Warrants NumberOfInputsUsedToDetermineValueOfWarrants	6	item
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1583000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2748000	USD
CY2014Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	300000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1200000	USD
CY2013Q4	us-gaap	Restructuring Charges RestructuringCharges	1900000	USD
CY2014Q2	us-gaap	Restructuring Reserve RestructuringReserve	570000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	1842000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	-1183000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-89000	USD
	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	78701041	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	38360000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1083000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5195000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	88278000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4120000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	11613000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552000	USD
CY2013Q4	us-gaap	Assets Assets	127563000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	79422000	USD
CY2014Q2	us-gaap	Assets Assets	117994000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10162000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	299000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10461000	USD
CY2013Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	14174000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10600000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	714000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10781000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9973000	USD
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61975416	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72869861	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	22714000	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11171000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	679000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	423593000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378522000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45751000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127563000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	36308000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	117994000	USD
	us-gaap	Interest Expense InterestExpense	729000	USD
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61975416	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72869861	shares
CY2014Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	36092000	USD
CY2014Q2	fold	Research Revenue ResearchRevenue	475000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	951000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3444000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	9000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9653000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	374000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	475000	USD
	fold	Research Revenue ResearchRevenue	931000	USD
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10725000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4830000	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	450000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	16005000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16005000	USD
	us-gaap	Interest Expense InterestExpense	19000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	515000	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9918000	USD
CY2014Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	1253000	USD
CY2014Q2	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2014Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	13104000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10800000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	748000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	789000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	444600000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	889000	USD
	us-gaap	Operating Expenses OperatingExpenses	33256000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33256000	USD
CY2014Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9978000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4753000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19970000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9929000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	396000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	808000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	14741000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14266000	USD
	us-gaap	Operating Expenses OperatingExpenses	30818000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29887000	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	111000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	78000	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-619000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-357000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-15349000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-14614000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32807000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-30557000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-12000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-4000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2291000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24161000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-607000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4245000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-155000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22039000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42434000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18170000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-11000	USD
CY2014Q2	us-gaap	Restructuring Charges RestructuringCharges	-81000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-3000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-11000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15361000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32818000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14618000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30560000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	115000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3157000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2748000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-2201000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-292000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	173000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	27994000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	575000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	13865000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	31114000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	28849000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2133000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	199000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-10495000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1736000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38360000	USD
	us-gaap	Restructuring Charges RestructuringCharges	-89000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-305000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11556000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12164000	shares
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15349000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14614000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32807000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30557000	USD
CY2014Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	475000	USD

Files In Submission

Name	View Source	Status
0001104659-14-058341-index-headers.html	Edgar Link	pending
0001104659-14-058341-index.html	Edgar Link	pending
0001104659-14-058341.txt	Edgar Link	pending
0001104659-14-058341-xbrl.zip	Edgar Link	pending
a14-14121_110q.htm	Edgar Link	pending
a14-14121_1ex10d3.htm	Edgar Link	pending
a14-14121_1ex10d4.htm	Edgar Link	pending
a14-14121_1ex31d1.htm	Edgar Link	pending
a14-14121_1ex31d2.htm	Edgar Link	pending
a14-14121_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fold-20140630.xml	Edgar Link	completed
fold-20140630.xsd	Edgar Link	pending
fold-20140630_cal.xml	Edgar Link	unprocessable
fold-20140630_def.xml	Edgar Link	unprocessable
fold-20140630_lab.xml	Edgar Link	unprocessable
fold-20140630_pre.xml	Edgar Link	unprocessable
g141211kgi001.jpg	Edgar Link	pending
g141211kii001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q3 Form 10-Q Financial Statement

#000110465914058341 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q3 Form 10-Q Financial Statement

#000110465914058341 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold